Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed London Stock Exchange - 04/24 11:29:58 am
1650 GBp   +0.46%
2h ago Zimmer to buy Biomet in $13.35 billion deal
3h ago NOVARTIS : Novarits Q1 profit rises, gains boosted by solid sales
5h ago EXCLUSIVE : Three employees at Marubeni's grain unit in China detained
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

GlaxoSmithKline plc : Glaxo's Malaria Drug Gets US Breakthrough Therapy Designation

12/20/2013 | 11:10am US/Eastern
Recommend:
0

By Rory Gallivan

LONDON--GlaxoSmithKline PLC (GSK.LN) Friday said the U.S. Food and Drug Administration has given its malaria treatment tafenoquine a designation that aims to speed up the approval process for drugs used to treat life-threatening diseases.

The FDA has granted tafenoquine Breakthrough Therapy designation, Glaxo said, adding that tafenoquine is not yet approved or licensed for use anywhere in the world.

-Shares at 1546 GMT, down a penny, or at 1,572 pence, valuing the company at GBP76.37 billion ($125.1 million).

Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Recommend :
0
React to this article
Latest news on GLAXOSMITHKLINE PLC
2h ago Zimmer to buy Biomet in $13.35 billion deal
3h ago NOVARTIS : Novarits Q1 profit rises, gains boosted by solid sales
5h ago EXCLUSIVE : Three employees at Marubeni's grain unit in China detained
6h ago Novartis sales miss forecast as readies overhaul
7h ago Novartis announces portfolio transformation, focusing company on leading busi..
7h agoDJNovartis 1Q Profit Rises About 23%
9h agoDJNovartis 1st Quarter Profit Rises About 23%
10h ago EXCLUSIVE : Marubeni says Chinese authorities detain three staff at grain unit
10h agoDJNovartis First-Quarter Profit Rises About 23% -- Update
1d ago Drug deals|lift shares
Advertisement
Chart
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Income Statement Evolution
GlaxoSmithKline plc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF